Evaluating First-Line BTK Inhibitors in Real-World, Older Chronic Lymphocytic Leukemia

Daniel Ermann, MD, discusses findings from a real-world study of first-line BTK inhibitors in older patients with chronic lymphocytic leukemia.

First-line zanubrutinib improved real-world treatment duration, time to next treatment, and survival in older chronic lymphocytic leukemia.